Provectus Biopharmaceuticals Presents PV-10® Data

KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that updated data from the company’s initial expansion cohort of patients with uveal melanoma metastatic to the liver ( mUM) in its cancers of the -Phase 1 liver trial of the investigational immunocatalyst PV-10 (NCT00986661) was part of two oral presentations on the 20e Congress of the International Society of Ocular Oncology (ISOO), held June 17-21, 2022 in Leiden, the Netherlands.

The first presentation, given by Krysta McVay, Research Nurse, Department of Melanoma Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer Center (MDACC), was titled “A Phase 1 Study of Percutaneous Autolytic Rose Bengal for patients with metastatic uveal melanoma with liver metastases A copy of his presentation is available on the Provectus website at: 2022.pdf.

Sapna Patel, MD, Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine and Director of the Uveal Melanoma Program at MDACC and Chair of the SWOG Cancer Research Network Melanoma Committee, made the second presentation titled “Metabolic Complete Responses (mCR) in Patients with Metastatic Uveal Melanoma (mUM) Treated with Image-Guided Injection of PV-10.” A copy of his presentation is available on the Society’s website at:

This ongoing single-center mUM study at MDACC has been led since its inception by Dr. Patel. Up to three mUM liver tumors can be injected per PV-10 treatment cycle. Response assessments are performed on day 28, then every three months thereafter. Patients with additional hepatic visceral, injectable MUM may receive additional cycles of PV-10 after Day 28. Eligible patients may also receive standard immune checkpoint blockade during and after treatment with PV-10 .

About Provectus

Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company that develops immunotherapy drugs for different disease areas based on a class of small molecules called halogenated xanthenes (HX). The Company’s flagship molecule is RBS. A second HX molecule was synthesized.

Provectus’ drug discovery and development programs include investigational drugs and drug targets in oncology (clinical stage), dermatology (clinical stage), hematology, virology, microbiology, ophthalmology (clinical stage) and animal health, and use several routes of intralesional (IL), topical (.top), oral (PO), inhaled (.inh), intranasal (IN) and intravenous (IV).

Information about the Company’s clinical trials is available on the National Institutes of Health (NIH) registry, For more information about Provectus, please visit the company’s website at

FORWARD-LOOKING STATEMENTS: Information in this press release may include “forward-looking statements”, within the meaning of United States securities laws, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of the management of the Company and are subject to various risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “budget”, “plan”, “continue”, “estimate”, “expect”, “plan”, “may”, “will”, “project”, “predict”, “potential”, “target”, “intend”, “could”, “could”, “should”, “believe” and similar words suggesting the future of results or statements about a prospect.

The safety and effectiveness of the agents and/or uses under investigation have not been established. There is no guarantee that agents will receive health authority approval or be commercially available in a country for the uses investigated or that these agents as products will achieve particular revenue levels.

Due to the risks, uncertainties and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result new information, future events or otherwise, except in accordance with applicable securities laws. Forward-looking statements are expressly qualified by this cautionary statement.

The risks, uncertainties and assumptions include those discussed in the documents filed by the Company with the Security and Exchange Commission (SECOND)including those described in Section 1A of:



Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Financial director
Phone: (866) 594-5999

Comments are closed.